WebDoctor Encyclopedia

Plasma-cell neoplasms

MGUS (monoclonal gammopathy of undetermined significance)

MGUS is a common, symptom-free blood finding in which a small clone of plasma cells makes a monoclonal protein. It is not cancer, but it carries a small yearly risk of turning into myeloma or a related disease.

Medically reviewed Last reviewed October 27, 2026

What is MGUS?

MGUS stands for monoclonal gammopathy of undetermined significance. It is a condition in which a small group of identical (clonal) plasma cells in the bone marrow makes an abnormal antibody protein, called a monoclonal protein or M-protein (also known as a paraprotein).

Plasma cells normally make many different antibodies to fight infection. In MGUS, one clone of plasma cells makes large amounts of a single antibody. This shows up as a sharp spike on a blood test called protein electrophoresis.

MGUS is not cancer and usually causes no symptoms. It is very common: about 3 in 100 people over 50 have it, and most never know.

It is usually found by chance during blood tests done for other reasons, such as checking kidney function, anaemia, nerve problems or a high protein level in the blood.

The importance of MGUS is that it carries a small risk of turning into a more serious condition. These include multiple myeloma, AL amyloidosis, Waldenstrom macroglobulinaemia and some lymphomas. The risk is about 1% per year.

Almost all cases of multiple myeloma are preceded by MGUS (Landgren et al., 2009). For this reason, people with MGUS are offered regular blood test monitoring.

1. Key facts at a glance

Feature Details
What it is A small plasma cell clone making a monoclonal protein
Is it cancer? No; it is a precursor condition
How common About 3% of people over 50 and about 5% over 70
Who is affected More common in men, older people and Black people
Symptoms Usually none
Risk of progression About 1% per year overall
Treatment Not needed; regular monitoring instead
Life expectancy Normal or near normal for most people

2. Types of MGUS

There are three main types, depending on which part of the antibody is made in excess. Each type tends to progress to different diseases.

Type What is found What it may progress to
Non-IgM MGUS (IgG, IgA) IgG or IgA M-protein; most common type, about 80% Multiple myeloma, AL amyloidosis
IgM MGUS IgM M-protein; about 15% Waldenstrom macroglobulinaemia, lymphoma, AL amyloidosis
Light-chain MGUS Only excess free light chains, no whole antibody Light-chain myeloma, AL amyloidosis

How MGUS is defined

The International Myeloma Working Group defines non-IgM MGUS as all of the following (Rajkumar et al., 2014):

  • M-protein below 30 g/L in the blood
  • Clonal plasma cells below 10% of the bone marrow, if a marrow test is done
  • No damage to organs caused by the plasma cells, such as high calcium, kidney damage, anaemia or bone lesions (known as “CRAB” features)
  • No AL amyloidosis or other related disease

If the M-protein is 30 g/L or more, or plasma cells reach 10% or more, without organ damage, the condition is called smouldering myeloma. That condition carries a higher risk of progression.

Condition M-protein Bone marrow plasma cells Organ damage Treatment
MGUS Below 30 g/L Below 10% None Monitoring only
Smouldering myeloma 30 g/L or more 10-59% None Monitoring; treatment for some high-risk cases
Multiple myeloma Usually present 10% or more Yes (high calcium, kidney damage, anaemia, bone lesions) or other myeloma-defining features Active treatment
AL amyloidosis Often small Often below 10% Yes, from amyloid deposits Active treatment

The main difference between MGUS and myeloma is therefore not only the amount of protein, but whether the clone is causing harm to the body.

3. Causes and risk factors

The cause of MGUS is not fully understood. It probably results from a combination of ageing of the immune system, genetic factors and long-term immune stimulation.

Risk factor Notes
Age The strongest factor; prevalence rises steadily after 50
Sex Slightly more common in men
Ethnicity About twice as common in Black people as in white people
Family history Close relatives of people with MGUS or myeloma have a higher risk
Obesity Linked with a modestly higher risk
Some exposures Pesticides and certain chemicals have been linked in studies
Chronic inflammation or autoimmune disease Associated in some studies

In a large study of people in Minnesota, MGUS was found in 3.2% of people aged 50 or over and 5.3% of those aged 70 or over (Kyle et al., 2006).

4. How does it look

MGUS has no visible signs on the body. People with it look and feel well, and it cannot be detected by examination.

It “looks” like something only on laboratory tests:

Test What is seen
Serum protein electrophoresis A narrow, sharp band or spike (the “M-spike”) in the gamma or beta region, instead of the normal broad hump
Immunofixation Identifies the type of M-protein, for example IgG kappa or IgA lambda
Serum free light chains May show an abnormal kappa-to-lambda ratio
Full blood count, calcium, kidney tests Normal in MGUS; abnormal results suggest another condition
Bone marrow (if done) A small proportion of clonal plasma cells, under 10%

When MGUS is not “undetermined”

Sometimes the M-protein itself causes harm even though the clone is small. Doctors then use more specific names:

Condition Meaning
MGRS (monoclonal gammopathy of renal significance) The protein damages the kidneys (Leung et al., 2019)
MGCS (monoclonal gammopathy of clinical significance) The protein damages other organs, such as the nerves or skin (Fermand et al., 2018)
IgM-related neuropathy The IgM protein attacks nerves, causing numbness and unsteadiness

These conditions often need treatment aimed at the clone, even though they are not cancers.

5. Symptoms

By definition, MGUS itself does not cause symptoms. People with MGUS are usually completely well.

Some people with MGUS have a slightly higher risk of:

  • Bone thinning (osteoporosis) and fractures
  • Infections
  • Blood clots in the veins
  • Peripheral neuropathy (numbness or tingling in the feet), especially with IgM MGUS

Warning signs of progression

New symptoms may mean MGUS has progressed or that a related condition has developed. Tell your doctor promptly about:

Symptom Possible meaning
New bone pain, especially in the back or ribs Myeloma
Increasing tiredness, paleness or breathlessness Anaemia from myeloma or Waldenstrom
Frequent or severe infections Weakened immune system
Excessive thirst, confusion or constipation High calcium
Foamy urine or swollen legs Kidney damage or AL amyloidosis
Numbness or tingling in the hands or feet Neuropathy or amyloidosis
Swollen lymph glands, night sweats, weight loss Lymphoma or Waldenstrom
Nosebleeds, blurred vision, headaches Thick blood (hyperviscosity) in IgM disease
Easy bruising around the eyes, large tongue AL amyloidosis

6. Diagnosis

MGUS is diagnosed when an M-protein is found and other conditions have been ruled out. Doctors usually do the following:

Test Purpose
Serum protein electrophoresis and immunofixation Measure and type the M-protein
Serum free light chain assay Measure kappa and lambda light chains and their ratio
Full blood count Check for anaemia
Calcium and kidney function Check for organ damage
Urine tests Look for protein or light chains in the urine
Bone marrow biopsy Not needed for everyone; done if risk is higher or results are unclear
Imaging Low-dose whole-body CT, MRI or PET-CT if there is any concern about bone disease or higher-risk MGUS
NT-proBNP and urine albumin Screen for amyloidosis when the light chain is abnormal

For low-risk MGUS with normal blood tests, a bone marrow test and imaging are usually not needed.

7. Risk of progression

Large long-term studies from the Mayo Clinic found that MGUS progresses at about 1% per year, and the risk never disappears, even after decades (Kyle et al., 2002; Kyle et al., 2018).

Mayo Clinic risk model

Doctors use three simple risk factors (Rajkumar et al., 2005):

  • M-protein of 15 g/L or more
  • Non-IgG type (IgA or IgM)
  • Abnormal free light chain ratio
Number of risk factors Risk group Risk of progression at 20 years
0 Low risk About 5%
1 Low-intermediate About 21%
2 High-intermediate About 37%
3 High risk About 58%

These figures do not take into account that many older people die of unrelated causes first. The real chance of developing myeloma or a related disease in a person’s lifetime is therefore lower.

About half of people with MGUS are in the low-risk group.

8. Management and follow-up

MGUS does not need treatment. Studies have not shown that treating MGUS prevents progression, and treatment would carry side effects.

Instead, people are monitored with regular blood tests so that progression can be picked up early.

Risk group Typical monitoring
Low risk Repeat tests after 6 months; if stable, every 2-3 years or only if symptoms develop
Intermediate or high risk Repeat tests after 6 months, then every year for life
IgM MGUS Yearly tests, including a check for swollen glands and an enlarged spleen
Light-chain MGUS Yearly free light chain and kidney checks

Looking after your general health

  • Bone health: ask about a bone density scan, vitamin D and calcium, and treatment if you have osteoporosis
  • Vaccinations: keep up to date with flu, pneumococcal, COVID-19 and other recommended vaccines
  • Infections: seek prompt treatment for infections
  • Blood clots: be aware of signs of a clot, such as a painful swollen leg
  • Medicines: tell your doctors you have MGUS before having contrast dye or certain drugs that could affect the kidneys

Should people be screened?

Routine screening of healthy people for MGUS is not recommended. Large studies are investigating whether screening could help catch myeloma earlier.

9. Outlook (prognosis)

For most people the outlook is excellent. MGUS usually remains stable for many years, and most people with it never develop myeloma or a related disease.

People with MGUS have slightly shorter survival on average than the general population in long-term studies. This is partly due to progression and partly due to associated conditions such as infections and fractures (Kyle et al., 2018).

If progression happens, regular monitoring means it is usually caught before serious complications develop. Modern treatments for myeloma and related conditions are much more effective than they were in the past.

10. Living with MGUS

Learning that you have an abnormal blood protein can cause worry, particularly when the word “myeloma” is mentioned. It helps to remember that MGUS is common, is not cancer and usually causes no harm.

Worry What helps
Fear of cancer Understanding your personal risk group and that most people never progress
Anxiety before blood tests Agreeing a clear monitoring plan and knowing whom to contact
Family risk Relatives are not routinely tested, but can mention the family history to their doctor
Lifestyle There are no special diet rules; a healthy weight and regular activity support overall health

11. Frequently asked questions

Question Answer
Is MGUS cancer? No. It is a precursor condition with a small risk of becoming cancer
Will it turn into myeloma? Most people never develop myeloma; the risk is about 1% per year
Can MGUS go away? Usually it persists, though levels may stay stable for decades
Do I need treatment? No, unless the protein is causing organ damage (MGRS or MGCS)
Can I do anything to lower the risk? No proven measures exist, but keeping healthy and attending follow-up is important

12. Questions to ask your doctor

  • What type of MGUS do I have, and what is my risk group?
  • How often will I need blood tests, and who will arrange them?
  • Do I need a bone marrow test or scans?
  • Which symptoms should make me contact you sooner?
  • Should I have a bone density scan?
  • Could my MGUS be linked to any of my other health problems, such as kidney or nerve problems?

Resources

  1. Kyle, R.A. et al. (2002) ‘A long-term study of prognosis in monoclonal gammopathy of undetermined significance’, New England Journal of Medicine, 346(8), pp. 564-569.
  2. Kyle, R.A. et al. (2006) ‘Prevalence of monoclonal gammopathy of undetermined significance’, New England Journal of Medicine, 354(13), pp. 1362-1369.
  3. Kyle, R.A. et al. (2018) ‘Long-term follow-up of monoclonal gammopathy of undetermined significance’, New England Journal of Medicine, 378(3), pp. 241-249.
  4. Rajkumar, S.V. et al. (2005) ‘Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance’, Blood, 106(3), pp. 812-817.
  5. Rajkumar, S.V. et al. (2014) ‘International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma’, The Lancet Oncology, 15(12), pp. e538-e548.
  6. Landgren, O. et al. (2009) ‘Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study’, Blood, 113(22), pp. 5412-5417.
  7. Leung, N. et al. (2019) ‘The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group’, Nature Reviews Nephrology, 15(1), pp. 45-59.
  8. Fermand, J.P. et al. (2018) ‘Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications’, Blood, 132(14), pp. 1478-1485.
  9. National Cancer Institute (2026) Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/myeloma/hp/myeloma-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.